Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors.
Curr Oncol Rep
; 26(5): 551-561, 2024 05.
Article
em En
| MEDLINE
| ID: mdl-38598035
ABSTRACT
PURPOSE OF REVIEW To provide insights into the role of peptide receptor radionuclide therapy (PRRT) in patients with advanced neuroendocrine tumors (NET) and an overview of possible strategies to combine PRRT with locoregional and systemic anticancer treatments. RECENT FINDINGS:
Research on combining PRRT with other treatments encompasses a wide variety or treatments, both local (transarterial radioembolization) and systemic therapies, chemotherapy (i.e., capecitabine and temozolomide), targeted therapies (i.e., olaparib, everolimus, and sunitinib), and immunotherapies (e.g., nivolumab and pembrolizumab). Furthermore, PRRT shows promising first results as a treatment prior to surgery. There is great demand to enhance the efficacy of PRRT through combination with other anticancer treatments. While research in this area is currently limited, the field is rapidly evolving with numerous ongoing clinical trials aiming to address this need and explore novel therapeutic combinations.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tumores Neuroendócrinos
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article